BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32006388)

  • 1. A retrospective study of myeloid leukaemia in children with Down syndrome in Ireland.
    Dowling GP; Piccin A; Gavin KT; Betts DR; Malone A; Cotter M; Sills A; Evans P; O' Marcaigh A; Smith OP
    Ir J Med Sci; 2020 Aug; 189(3):979-984. PubMed ID: 32006388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Child and adolescent Down syndrome-associated leukaemia: the Irish experience.
    O'Rafferty C; Kelly J; Storey L; Ryan C; O'Marcaigh A; Smith O
    Ir J Med Sci; 2015 Dec; 184(4):877-82. PubMed ID: 25344131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
    McElwaine S; Mulligan C; Groet J; Spinelli M; Rinaldi A; Denyer G; Mensah A; Cavani S; Baldo C; Dagna-Bricarelli F; Hann I; Basso G; Cotter FE; Nizetic D
    Br J Haematol; 2004 Jun; 125(6):729-42. PubMed ID: 15180862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
    Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
    Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of GATA1 mutations in Down syndrome.
    Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
    Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
    Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
    Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
    Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
    BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute megakaryoblastic leukemia in Down syndrome.
    Hitzler JK
    Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
    Xavier AC; Ge Y; Taub JW
    J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
    Nikolaev SI; Santoni F; Vannier A; Falconnet E; Giarin E; Basso G; Hoischen A; Veltman JA; Groet J; Nizetic D; Antonarakis SE
    Blood; 2013 Jul; 122(4):554-61. PubMed ID: 23733339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia.
    Qi H; Mao Y; Cao Q; Sun X; Kuai W; Song J; Ma L; Hong Z; Hu J; Zhou G
    Med Sci Monit; 2020 Jun; 26():e922662. PubMed ID: 32532951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome for Down syndrome patients with hematopoietic disorders.
    Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
    J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
    Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
    Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
    Hama A; Muramatsu H; Makishima H; Sugimoto Y; Szpurka H; Jasek M; O'Keefe C; Takahashi Y; Sakaguchi H; Doisaki S; Shimada A; Watanabe N; Kato K; Kiyoi H; Naoe T; Kojima S; Maciejewski JP
    Br J Haematol; 2012 Feb; 156(3):316-25. PubMed ID: 22122069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.